Fulgent Genetics (FLGT) Income from Non-Controlling Interests (2021 - 2026)
Fulgent Genetics (FLGT) posted Income from Non-Controlling Interests of -$189000.0 for Q2 2026, up 57.81% sequentially from -$448000.0 in Q1 2026, and up 36.79% YoY from -$138168.7 in Q2 2025.
Fulgent Genetics (FLGT) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Fulgent Genetics has reported Income from Non-Controlling Interests for 6 years, with the latest figure at -$189000.0 in Q2 2026.
- Quarterly Income from Non-Controlling Interests rose 36.79% year-over-year to -$189000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.1 million (down 6.99% YoY) and the FY2025 annual result came in at -$1.1 million, down 0.54% from the prior year.
- Income from Non-Controlling Interests rose to -$189000.0 in Q2 2026 per FLGT's latest filing, from -$448000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$46000.0 in Q3 2024 and troughed at -$6.2 million in Q4 2023.
- A 5-year average of -$653388.9 and a median of -$365000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests tumbled 2434.84% in 2023, then soared 95.12% in 2024.
- Over 5 years, Income from Non-Controlling Interests stood at -$244000.0 in 2022, then sank by 2434.84% to -$6.2 million in 2023, then jumped by 95.12% to -$302000.0 in 2024, then advanced by 23.18% to -$232000.0 in 2025, then gained by 18.53% to -$189000.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$189000.0, -$448000.0, and -$232000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.44 Bn | 209.37 Bn | 8.34 Bn | 5.00 Mn |
| 2 | Danaher | 139.95 Bn | 135.60 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 46.16 Bn | 45.96 Bn | 779.09 Mn | - |
| 4 | Agilent Technologies | 39.67 Bn | 37.87 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.29 Bn | 37.21 Bn | 1.44 Bn | 2.00 Mn |
| 6 | Natera | 38.61 Bn | 37.51 Bn | 696.04 Mn | - |
| 7 | Illumina | 29.99 Bn | 28.82 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.57 Bn | 28.51 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.17 Bn | 25.55 Bn | 1.03 Bn | 14.00 Mn |
| 10 | Fulgent Genetics | 515.29 Mn | 258.26 Mn | 25.68 Mn | -189,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -189,000.00 |
| Mar 31, 2026 | -448,000.00 |
| Dec 31, 2025 | -232,000.00 |
| Sep 30, 2025 | -218,000.00 |
| Jun 30, 2025 | -299,000.00 |
| Mar 31, 2025 | -369,000.00 |
| Dec 31, 2024 | -302,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -380,000.00 |
| Mar 31, 2024 | -384,000.00 |
| Dec 31, 2023 | -6.19 Mn |
| Sep 30, 2023 | -359,000.00 |
| Jun 30, 2023 | -361,000.00 |
| Mar 31, 2023 | -509,000.00 |
| Dec 31, 2022 | -244,000.00 |
| Sep 30, 2022 | -376,000.00 |
| Jun 30, 2022 | -438,000.00 |
| Mar 31, 2022 | -422,000.00 |
| Dec 31, 2021 | -662,000.00 |
| Sep 30, 2021 | -298,000.00 |